RT Journal Article
SR Electronic
T1 A simulation-based procedure to estimate base rates from Covid-19 antibody test results I: Deterministic test reliabilities
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.28.20075036
DO 10.1101/2020.04.28.20075036
A1 Joosten, Reinoud
A1 Abhishta, Abhishta
YR 2020
UL http://medrxiv.org/content/early/2020/05/09/2020.04.28.20075036.abstract
AB We design a procedure (the complete Python code may be obtained at https://github.com/abhishta91/antibody_montecarlo) using Monte Carlo (MC) simulation to establish the point estimators described below and confidence intervals for the base rate of occurence of an attribute (e.g., antibodies against Covid-19) in an aggregate population (e.g., medical care workers) based on a test. The requirements for the procedure are the test’s sample size (N) and total number of positives (X), and the data on test’s reliability.The modus is the prior which generates the largest frequency of observations in the MC simulation with precisely the number of test positives (maximum-likelihood estimator). The median is the upper bound of the set of priors accounting for half of the total relevant observations in the MC simulation with numbers of positives identical to the test’s number of positives.Our rather preliminary findings areThe median and the confidence intervals suffice universally.The estimator may be outside of the two-sided 95% confidence interval.Conditions such that the modus, the median and another promising estimator which takes the reliability of the test into account, are quite close.Conditions such that the modus and the latter estimator must be regarded as logically inconsistent.Conditions inducing rankings among various estimators relevant for issues concerning over-or underestimation.JEL-codes: C11, C13, C63Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received for this work.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yeshttps://github.com/abhishta91/antibody_montecarlo https://github.com/abhishta91/antibody_montecarlo